MorphoSys AG (MOR) 2012年年度报告「NASDAQ」.pdf

1、 ANTIBODIESCONNECTANNUAL REPORT 2012 Program/PartnerIndicationDiscoveryPreclinicPhase 1Phase 2Phase 3Market MOR208Cancer MOR103Rheumatoid arthritisMultiple sclerosis MOR202Multiple myeloma Early-stage ProgramsInfl ammationInfectious diseases Gantenerumab/RocheAlzheimers disease CNTO1959/Janssen Biot

2、echPsoriasisRheumatoid arthritis Novartisnot.discl.BHQ880/NovartisCancer BYM338/NovartisMusculoskeletal LFG316/NovartisOphthalmology OMP-59R5/Oncomed/GSKCancer BAY94-9343/BayerCancer Boehringer Ingelheimnot.discl.CNTO3157/Janssen BiotechAsthma Janssen BiotechInfl ammation LJM716/NovartisCancer VAY73

3、6/NovartisInfl ammation Vantictumab/OncomedCancer Pfi zerCancer 20 Partnered Programs 34 Partnered Programs 6 Proprietary Programs70 Partnered ProgramsProduct PipelineMORPHOSYSS PRODUCT PIPELINE AS OF 31 DECEMBER 2012ANTIBODIESCONNECTTherapeutic antibodies can bind disease relevant target molecules

4、or attach themselves to pathogens.Modern life science aims to exploit this basic function of antibodies to improve patients lives.Therapeutic antibodies likewise can link different stories together,different people,their professions,sometimes their entire lives:patients,doctors,scientists,investors

5、and many more.In the context of our Annual Report 2012 antibodies fi guratively build bridges between print and online media.You will fi nd several references and links to additional back-ground information online.we encourage you,dear reader,to explore these connections.CONNECTANTIBODIES BASICSwhat

6、 are antibodies?how do these molecules look like?what do they do?Antibodies can accurately bind and detect almost any molecule.They are an essential component of the human immune system.Using antibodies to fi ght diseases is a logical extension of their natural role./LEARN MORE ABOUT ANTIBODIES IN O